Cargando…
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
SIMPLE SUMMARY: Advanced biliary tract cancer is difficult to treat, and 5-year survival is less than 5% for tumours that cannot be removed by surgery. CAP7.1 is a drug being investigated for biliary tract cancer. This study assessed treatment with CAP7.1 in patients with advanced biliary tract canc...
Autores principales: | Pape, Ulrich-Frank, Kasper, Stefan, Meiler, Johannes, Sinn, Marianne, Vogel, Arndt, Müller, Lothar, Burkhard, Oswald, Caca, Karel, Heeg, Steffen, Büchner-Steudel, Petra, Rodriguez-Laval, Victor, Kühl, Anja A, Arsenic, Ruza, Jansen, Holger, Treasure, Peter, Utku, Nalân |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692271/ https://www.ncbi.nlm.nih.gov/pubmed/33121007 http://dx.doi.org/10.3390/cancers12113149 |
Ejemplares similares
-
Immunohistochemical analysis of PDK1 expression in breast cancer
por: Arsenic, Ruza
Publicado: (2014) -
Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma
por: Goeppert, Benjamin, et al.
Publicado: (2019) -
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
por: Arsenic, Ruza, et al.
Publicado: (2015) -
Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy
por: Arsenic, Ruza, et al.
Publicado: (2015) -
Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids
por: Prasad, Vikas, et al.
Publicado: (2015)